

Trust Headquarters  
Russell's Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ

**Ref:** FOI-062024-000949

**Date:** 01/07/2024

**Address / Email:**

Dear

**Request Under Freedom of Information Act 2000**

Thank you for requesting information under the Freedom of Information Act 2000.

Request

**Dear The Dudley Group NHS Foundation Trust,**

**I have a freedom of information request regarding the treatment of renal cell carcinoma. Could you please answer the following questions:**

**Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage) :**

- **Avelumab + Axitinib**
- **Axinitib**
- **Cabozantinib**
- **Everolimus**
- **Lenvatinib + Everolimus**
- **Lenvatinib + Pembrolizumab**
- **Nivolumab monotherapy**
- **Nivolumab + Cabozantinib**
- **Nivolumab + Ipilimumab**
- **Pazopanib**
- **Pembrolizumab monotherapy**
- **Pembrolizumab + Axitinib**
- **Radiotherapy only**
- **Sunitinib**
- **Temsirolimus**
- **Tivozanib**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

**Q2. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?**

**Q3. In the last 3 months, how many patients have been initiated\* on the following agents for treatment for Renal Cell Carcinoma?**

- Nivolumab (monotherapy)
- Nivolumab + Ipilimumab
- Nivolumab + Cabozantinib
- Lenvatinib + Pembrolizumab
- Avelumab + Axitinib

\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q4. Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?

**Response**

Questions	Responses
<p>Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):</p> <ul style="list-style-type: none"> <li>• Avelumab + Axitinib</li> <li>• Axitinib</li> <li>• Cabozantinib</li> <li>• Everolimus</li> <li>• Lenvatinib + Everolimus</li> <li>• Lenvatinib + Pembrolizumab</li> <li>• Nivolumab monotherapy</li> <li>• Nivolumab + Cabozantinib</li> <li>• Nivolumab + Ipilimumab</li> <li>• Pazopanib</li> <li>• Pembrolizumab monotherapy</li> <li>• Pembrolizumab + Axitinib</li> <li>• Radiotherapy only</li> <li>• Sunitinib</li> <li>• Temsirolimus</li> <li>• Tivozanib</li> <li>• Other active systemic anti-cancer therapy</li> <li>• Palliative care only</li> </ul>	<p>The Trust does not publish numbers lower than 5 as this could lead to the identification of the person(s) involved and cause distress to families and friends. The number of patients treated in the last 3 months with the following agents for renal cell carcinoma over the years requested is less than 5, therefore Section 40(2) of the Freedom of Information Act has been applied.</p>
<p>Q2. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?</p>	<p>This is not recorded in Chemocare.</p>
<p>Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?</p> <ul style="list-style-type: none"> <li>• Nivolumab (monotherapy)</li> <li>• Nivolumab + Ipilimumab</li> <li>• Nivolumab + Cabozantinib</li> <li>• Lenvatinib + Pembrolizumab</li> <li>• Avelumab + Axitinib</li> </ul> <p>*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.</p>	<p>0</p>
<p>Q4. Does your trust participate in any clinical trials for the treatment of renal cell</p>	<p>No</p>

<b>carcinoma? If so, please provide the name of each trial and number of patients that are taking part?</b>	
---	--

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager  
Trust Headquarters  
Russell's Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ  
Email: [dgft.dpo@nhs.net](mailto:dgft.dpo@nhs.net)

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
SK9 5AF  
Tel: 0303 123 1113  
[www.ico.org.uk](http://www.ico.org.uk)

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team  
The Dudley Group NHS Foundation Trust**